Sanofi Stock News

Availability of the aide-mémoire for Q3 2026 results Paris, France – October 6, 2026. Sanofi announced today the availability of the aide-mémoire for Q3 2026 results on the "Investors" page of sanofi.com: Third quarter 2026 results Prepared each quarter, this document is intended to support financial modelling of the quarterly results.

NEW YORK--(BUSINESS WIRE)--Weitz & Luxenberg, which represents more people in the Dupixent litigation than any other firm, appeared this past Friday at the first hearing in the federal multidistrict litigation over allegations that Dupixent (dupilumab) can cause, accelerate or unmask cutaneous T-cell lymphoma (CTCL). Judge Zahid N. Quraishi of the U.S. District Court for the District of New Jer...

The six-time NBA All-Star, three-time All-NBA selection, 2016 NBA Rookie of the Year, and 2026 NBA Champion Karl-Anthony Towns brings his personal experience with COVID-19 to encourage eligible people, especially those at increased risk, to learn about their vaccination options Towns shares why protecting his health remains a priority and encourages informed conversations about COVID-19 vaccina...

The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.

French drugmaker ​Sanofi said on Thursday it ‌would pay US partner Regeneron $1 billion upfront and up to $7 billion more ​in milestone payments to add ​four next-generation, long-acting immunology antibodies to ⁠the partnership behind their blockbuster ​eczema drug Dupixent.

Sanofi and Regeneron expand global Alliance with multiple nex t-generation, long-acting immunology antibodies REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the Alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting pre-clinical antibodies from Regeneron Regeneron to receive $1 billion upfront, with ...

European drugmakers called for ​beefed-up government spending on medicines, faster trials and IP protections as ‌they sounded warnings on Tuesday that the continent's pharmaceutical industry risks losing out to the United States and China.

Sanofi and  Cheplaphar m to create new strategic partnership i n mature medicines